Liver X Receptor

Choose Selective Liver X Receptor Inhibitors
Isoform-selective Inhibitors

Liver X Receptor Products

  • All (7)
  • Liver X Receptor Antagonist (1)
  • Liver X Receptor Agonists (6)
  • New Liver X Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
E1142New GSK2033 GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
S2630 GW3965 HCl GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.
Acta Neuropathol Commun, 2022, 10(1):40
Pharmacol Res, 2022, 178:106188
Nutrients, 2022, 14(12)2473
S6427 AZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.
J Clin Invest, 2019, 129(3):1129-1151
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Commun Biol, 2022, 5(1):132
Front Cardiovasc Med, 2021, 8:746989
Hepatology, 2020, 10.1002/hep.31594
S7934 SR9243 SR9243 is a potent and selective LXR inverse agonist.
Front Immunol, 2021, 12:732102
FEBS Lett, 2016, 590(11):1614-29
S8390 LXR-623 (WAY-252623) LXR-623 (WAY-252623) is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
Acta Neuropathol Commun, 2022, 10(1):40
EMBO Mol Med, 2019, 11(10):e10769
Cancers (Basel), 2019, 11(6)
S8689 Abequolixron (RGX-104) Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E1142New GSK2033 GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
S2630 GW3965 HCl GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.
Acta Neuropathol Commun, 2022, 10(1):40
Pharmacol Res, 2022, 178:106188
Nutrients, 2022, 14(12)2473
S6427 AZ876 AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.
J Clin Invest, 2019, 129(3):1129-1151
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
Commun Biol, 2022, 5(1):132
Front Cardiovasc Med, 2021, 8:746989
Hepatology, 2020, 10.1002/hep.31594
S7934 SR9243 SR9243 is a potent and selective LXR inverse agonist.
Front Immunol, 2021, 12:732102
FEBS Lett, 2016, 590(11):1614-29
S8390 LXR-623 (WAY-252623) LXR-623 (WAY-252623) is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.
Acta Neuropathol Commun, 2022, 10(1):40
EMBO Mol Med, 2019, 11(10):e10769
Cancers (Basel), 2019, 11(6)
S8689 Abequolixron (RGX-104) Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E1142New GSK2033 GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
Tags: Liver X Receptor inhibitor|Liver X Receptor agonist|Liver X Receptor activator|Liver X Receptor inducer|Liver X Receptor antagonist|Liver X Receptor signaling pathway|Liver X Receptor assay kit